Skip to main content

Table 1 Subgroup analysis and the pooled HR for patients

From: Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017

Outcomes No. of studies Heterogeneity (I2), % HR (95% CI) p for heterogeneity
OS
 Post-transplantation in CR 3 63.3 0.36 (0.17, 0.76) 0.066
 At transplantation in CR 7 47.6 0.43 (0.29, 0.63) 0.076
 Over 50 10 61.4 1.03 (1.01, 1.05) 0.006
 PBSC 4 66.7 1.02 (0.53, 1.96) 0.029
 aGVHD 3 0 2.25 (1.55, 3.27) 0.814
 cGVHD 4 39.4 0.32 (0.19, 0.55) 0.175
PFS
 Post-transplantation in CR 5 0 0.30 (0.23, 0.39) 0.609
 At transplantation in CR 7 35.7 0.59 (0.44, 0.78) 0.156
 Over 50 8 69.4 1.04 (1.01, 1.08) 0.002
 PBSC 3 47.2 0.80 (0.45, 1.42) 0.150
 aGVHD 2 0 1.27 (0.84, 1.94) 0.660
 cGVHD 5 39.5 0.45 (0.29, 0.69) 0.158
\